InvestorsHub Logo
Followers 29
Posts 4738
Boards Moderated 0
Alias Born 12/27/2007

Re: ariadndndough post# 33611

Wednesday, 08/28/2013 1:44:13 PM

Wednesday, August 28, 2013 1:44:13 PM

Post# of 80490
i am having troulbe copying page 18 in tabel format. but please go there and look PONA is such a superior drug and just needs time to play out.


Table 02: Effect of Ponatinib, Imatinib, Nilotinib, and Dasatinib on Viability of Ba/F3 Cells Dependent on Native or 14 Mutant Variants of BCR-ABL
Ba/F3 Cell Viability Assay
IC50 (nM)
BCR-ABL
Ponatinib1
Imatinib2
Nilotinib2
Dasatinib2
Native
0.5
260
13
0.8
M244V
2.2
2000
38
1.3
G250E
4.1
1350
48
1.8
Q252H
2.2
1325
70
3.4
Y253F
2.8
3475
125
1.4
Y253H
6.2
>6400
450
1.3
E255K
14
5200
200
5.6
E255V
36
>6400
430
11
T315A
1.6
971
61
125
T315I
11
>6400
>2000
>200
F317L
1.1
1050
50
7.4
F317V
10
350
nd
53
M351T
1.5
880
15
1.1
F359V
10
1825
175
2.2
H396P
1.1
850
41
0.6
Parental
1713
>6400
>2000
>200
1: Report OHSU-001
2: O'Hare T. et al (2005) Cancer Res. 65: 4500-4505. O'Hare T. et al (2007) Blood. 110: 2242-2249.
nd=not determined

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.